501 related articles for article (PubMed ID: 33104270)
21. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.
Guo F; Wang Y; Liu J; Mok SC; Xue F; Zhang W
Oncogene; 2016 Feb; 35(7):816-26. PubMed ID: 25961926
[TBL] [Abstract][Full Text] [Related]
22. Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling.
Goffart N; Kroonen J; Di Valentin E; Dedobbeleer M; Denne A; Martinive P; Rogister B
Neuro Oncol; 2015 Jan; 17(1):81-94. PubMed ID: 25085362
[TBL] [Abstract][Full Text] [Related]
23. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
24. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
25. The critical roles of tumor-initiating cells and the lymph node stromal microenvironment in human colorectal cancer extranodal metastasis using a unique humanized orthotopic mouse model.
Margolin DA; Myers T; Zhang X; Bertoni DM; Reuter BA; Obokhare I; Borgovan T; Grimes C; Green H; Driscoll T; Lee CG; Davis NK; Li L
FASEB J; 2015 Aug; 29(8):3571-81. PubMed ID: 25962655
[TBL] [Abstract][Full Text] [Related]
26. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4.
Yi L; Zhou X; Li T; Liu P; Hai L; Tong L; Ma H; Tao Z; Xie Y; Zhang C; Yu S; Yang X
J Exp Clin Cancer Res; 2019 Aug; 38(1):339. PubMed ID: 31382985
[TBL] [Abstract][Full Text] [Related]
27. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
[TBL] [Abstract][Full Text] [Related]
28. CXCR4 Ligands: The Next Big Hit?
Walenkamp AME; Lapa C; Herrmann K; Wester HJ
J Nucl Med; 2017 Sep; 58(Suppl 2):77S-82S. PubMed ID: 28864616
[TBL] [Abstract][Full Text] [Related]
29. A review on CXCR4/CXCL12 axis in oncology: no place to hide.
Domanska UM; Kruizinga RC; Nagengast WB; Timmer-Bosscha H; Huls G; de Vries EG; Walenkamp AM
Eur J Cancer; 2013 Jan; 49(1):219-30. PubMed ID: 22683307
[TBL] [Abstract][Full Text] [Related]
30. [Clinical relevance of chemokine receptor CXCR4].
Gębura K; Bogunia-Kubik K
Postepy Hig Med Dosw (Online); 2012 May; 66():252-66. PubMed ID: 22706111
[TBL] [Abstract][Full Text] [Related]
31. MSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy?
Ghasemi K; Ghasemi K
Int Immunopharmacol; 2022 Jul; 108():108863. PubMed ID: 35623288
[TBL] [Abstract][Full Text] [Related]
32. Breast tumor metastasis following filgrastim administration due to the SDF-1/CXCR4 pathway.
Khalighfard S; Khori V; Esmati E; Ahmadi F; Amiriani T; Poorkhani A; Sadani S; Khodayari S; Khodayari H; Kalhori MR; Keshavarz P; Alizadeh AM
Med Oncol; 2023 Jan; 40(2):74. PubMed ID: 36609711
[TBL] [Abstract][Full Text] [Related]
33. CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications.
Yang Y; Li J; Lei W; Wang H; Ni Y; Liu Y; Yan H; Tian Y; Wang Z; Yang Z; Yang S; Yang Y; Wang Q
Int J Biol Sci; 2023; 19(11):3341-3359. PubMed ID: 37497001
[TBL] [Abstract][Full Text] [Related]
34. Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells.
Yi T; Zhai B; Yu Y; Kiyotsugu Y; Raschle T; Etzkorn M; Seo HC; Nagiec M; Luna RE; Reinherz EL; Blenis J; Gygi SP; Wagner G
Proc Natl Acad Sci U S A; 2014 May; 111(21):E2182-90. PubMed ID: 24782546
[TBL] [Abstract][Full Text] [Related]
35. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
36. Role of CXCR4 and SDF1 as prognostic factors for survival and the association with clinicopathology in colorectal cancer: A systematic meta-analysis.
Li YP; Pang J; Gao S; Bai PY; Wang WD; Kong P; Cui Y
Tumour Biol; 2017 Jun; 39(6):1010428317706206. PubMed ID: 28621237
[TBL] [Abstract][Full Text] [Related]
37. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion.
Kucia M; Jankowski K; Reca R; Wysoczynski M; Bandura L; Allendorf DJ; Zhang J; Ratajczak J; Ratajczak MZ
J Mol Histol; 2004 Mar; 35(3):233-45. PubMed ID: 15339043
[TBL] [Abstract][Full Text] [Related]
38. Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.
Katsura M; Shoji F; Okamoto T; Shimamatsu S; Hirai F; Toyokawa G; Morodomi Y; Tagawa T; Oda Y; Maehara Y
Cancer Sci; 2018 Jan; 109(1):154-165. PubMed ID: 29032612
[TBL] [Abstract][Full Text] [Related]
39. [Correlations of chemokine CXCL12 and its receptor to tumor metastasis].
Jiang YP; Wu XH
Ai Zheng; 2007 Feb; 26(2):220-4. PubMed ID: 17298758
[TBL] [Abstract][Full Text] [Related]
40. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
